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Background and purpose   Cyclooxygenase-2 (COX-2) promotes 
inflammation by synthesizing pro-inflammatory prostaglandins 
from arachidonic acid. Inflammation is an early response to bone 
fracture, and ablation of COX-2 activity impairs fracture healing. 
Arachidonic acid is also converted into leukotrienes by 5-lipoxy-
genase (5-LO). We hypothesized that 5-LO is a negative regulator 
of fracture healing and that in the absence of COX-2, excess leu-
kotrienes synthesized by 5-LO will impair fracture healing.
Methods   Fracture healing was assessed in mice with a tar-
geted 5-LO mutation (5-LOKO mice) and control mice by radio-
graphic and histological observations, and measured by histo-
morphometry and torsional mechanical testing. To assess effects 
on arachidonic acid metabolism, prostaglandin E2, F2a, and leu-
kotriene B4 levels were measured in the fracture calluses of con-
trol, 5-LOKO COX-1KO, and COX-2KO mice by enzyme linked 
immunoassays. 
Results   Femur fractures in 5-LOKO mice rapidly developed a 
cartilaginous callus that was replaced with bone to heal fractures 
faster than in control mice. Femurs from 5-LOKO mice had sub-
stantially better mechanical properties after 1 month of healing 
than did control mice. Callus leukotriene levels were 4-fold higher 
in mice homozygous for a targeted mutation in the COX-2 gene 
(COX-2KO), which indicated that arachidonic acid was shunted 
into the 5-LO pathway in the absence of COX-2.
Interpretation   These experiments show that 5-LO negatively 
regulates fracture healing and that shunting of arachidonic acid 
into  the  5-LO  pathway  may  account,  at  least  in  part,  for  the 
impaired fracture healing response observed in COX-2KO mice.
 
The molecular events that initiate and maintain bone fracture 
healing are poorly understood. Inflammation is an early physi-
ological response to fracture and it has been postulated that 
signaling molecules produced during inflammation initiate the 
tissue regeneration pathway (Mountziaris and Mikos 2008, 
Cottrell et al. 2009).
Cyclooxygenase-2 (COX-2) is a critical, enzymatic regula-
tor of inflammation (Simmons et al. 2004). Loss of COX-2 
function dramatically impairs fracture healing in mice and 
rats (Simon et al. 2002). Fracture healing in COX-2 knock-out 
mice is characterized by formation of a small cartilaginous 
fracture  callus  with  delayed,  reduced,  or  no  endochondral 
bone formation (Zhang et al. 2002). Pharmacological inhibi-
tion of COX-2 also severely impairs fracture healing (Simon 
and O’Connor 2007). Human studies examining the effects of 
non-steroidal anti-inflammatory drugs on fracture healing sup-
port the conclusions from animal studies (Burd et al. 2003).
Inflammatory stimuli activate phospholipase A2 to release 
arachidonic acid from membrane stores (Capper and Marshall 
2001). In turn, arachidonic acid is converted into prostaglan-
dins by COX-2 or into leukotrienes by 5-lipoxygenase (5-LO) 
(Murphy and Gijon 2007). By inhibiting COX-2, arachidonic 
acid can be shunted into the 5-LO pathway to produce abnor-
mally high levels of leukotrienes (Hudson et al. 1993, Mar-
tel-Pelletier et al. 2004, Marcouiller et al. 2005). Conversely, 
ablation of 5-LO function can lead to abnormally high levels 
of prostaglandins (Byrum et al. 1997). Since COX-2 activity 
is critical for successful fracture healing, loss of COX-2 activ-
ity may alter fracture callus prostaglandin levels and lead to 
excess leukotriene synthesis. In turn, these excess amounts of 
leukotrienes could contribute to the impaired healing observed 
in mice lacking COX-2 or in animals treated with COX-2 
inhibitors by altering the inflammatory response.
To test this hypothesis, we measured fracture healing in 
mice homozygous for a targeted mutation in the 5-LO gene 
(5-LOKO mice) as loss of 5-LO activity would prevent leu-
kotriene synthesis and potentially lead to accelerated healing. 
Fracture healing was assessed by radiography, histomorphom-
etry, and torsional mechanical testing. Levels of fracture callus 
prostaglandin (PG) E2, PGF2a and leukotriene (LT) B4 were 
measured to determine how loss of COX-1, COX-2, or 5-LO 
activity alters the synthesis of these lipid signaling molecules 
during fracture healing.Acta Orthopaedica 2010; 81 (6): 748–755  749
Materials and methods
Animal procedures
All animal experiments were approved by the Institutional 
Animal  Care  and  Use  Committee  of  New  Jersey  Medi-
cal  School.  Experimental  mice  homozygous  for  inactivat-
ing  mutations  in  the  5-lipoxygenase,  cyclooxygenase-1,  or 
cyclooxygenase-2 gene (5-LOKO, COX-1KO, and COX-2KO, 
respectively) were obtained from breeding colonies. Founder 
mice were obtained from Jackson Laboratories (Alox5tm1Fun 
(5-LOKO);  Bar  Harbor,  ME)  or  from  Taconic  (Ptgs1tm1Unc 
and  Ptgs2tm1Unc  (COX-1KO  and  COX-2KO);  Germantown, 
NY) (Chen et al. 1994, Langenbach et al. 1995, Morham et 
al. 1995). The 5-LOKO mice had been backcrossed into the 
C57BL/6 background and so C57BL/6 mice purchased from 
Jackson Laboratories were used as the control for the 5-LOKO 
mice. The COX-1KO and COX-2KO mice have a B6;129P2 
mixed genetic background and so wild-type (B6;129P2) and 
COX-2  heterozygous  (COX-2Het)  mice  obtained  from  the 
COX-2KO breeding colony were used as controls for the COX-
1KO and COX-2KO strains. Mouse genotypes were confirmed 
by PCR analysis of tail biopsy DNA samples using recom-
binant Pwo polymerase (Dabrowski and Kur 1998). Experi-
ments were performed on female mice only. Mice were 10–12 
weeks old at the time of fracture. 
Closed  femur  fractures  were  produced  in  the  right  hind 
limb of mice using an established procedure (Manigrasso and 
O’Connor 2004). Mice were anesthetized with a mixture of 
ketamine and xylazine. A 0.254-mm diameter stainless steel 
pin was inserted retrograde into the femoral canal and wedged 
in place with the tip of a 0.255-mm diameter needle. The 
fracture was produced using a custom-made 3-point bending 
device. The mice were allowed to ambulate freely following 
fracture and were provided food and water ad libitum. They 
were killed with an inhaled overdose of halothane anesthesia.
Torsional mechanical testing
The mechanical strength of the mouse femurs was determined 
by torsional mechanical testing to failure as described previ-
ously (Manigrasso and O’Connor 2004). Testing was accom-
plished  using  a  servohydraulic  testing  machine  (MTS Test 
Star, Eden Prairie, MN), a 20-Nm reaction torque cell (Inter-
face, Scottsdale, AZ), at an actuator head displacement rate 
of 1 degree per second. Peak torque, rigidity, maximum shear 
stress, and shear modulus were calculated from the torque-
displacement  curves  and  callus  dimensions  as  previously 
described (Manigrasso and O’Connor 2004). Femur cortical 
bone thickness was measured from cross sections of intact 
femurs from C57BL/6 (0.166 (0.004) mm, n = 9) and 5-LOKO 
(0.174 (0.003), n = 9) that were approximately 14 weeks old. 
The fractured and contralateral femurs from each mouse were 
tested at 4 and 12 weeks after fracture. Values for each frac-
tured femur were normalized to the corresponding contralat-
eral femur as a percentage. The normalized values for each 
parameter were compared between the 5-LOKO and C57BL/6 
mice using Student’s t-tests at each time point. 
Radiography, histology, and histomorphometry
All animals were examined by radiography immediately after 
fracture to ensure fracture quality, and after killing to assess 
healing and any morbid conditions. Three 5-LOKO and three 
C57BL/6 mice were examined by radiography periodically 
throughout healing. Radiographs were taken using a Model 
804 Packard Faxitron (Field Emission Corp., McMinnville, 
OR)  and  Kodak  MINR2000  mammography  film  (Eastman 
Kodak, Rochester, NY).
For  histology  and  histomorphometry,  fractured  femurs 
were  embedded  in  polymethylmethacrylate  using  standard 
procedures  (Baron  et  al.  1983).  Specimens  were  sectioned 
longitudinally using a diamond wafering saw and polished 
with alumina grit prior to staining with van Gieson’s picro-
fuchsin (where mineralized tissue stains red) and Stevenel’s 
blue (where proteoglycan stains deep blue) (Maniatopoulos 
et al. 1986). Digital images of each specimen were captured 
and  analyzed  using  Image  Pro  software  version  5  (Media 
Cybernetics, Bethesda, MD). Callus, cartilage, and mineral-
ized tissue area were measured. The cartilage and mineralized 
tissue area were normalized to callus area as a percentage for 
each specimen. Data for callus area, per cent cartilage, and 
per cent mineralized tissue were initially analyzed by 2-way 
ANOVA using genotype and time after fracture as the inde-
pendent variables. The analysis found differences for callus 
area (p = 0.02), per cent cartilage (p < 0.001), and per cent 
mineralized tissue (p = 0.04). Fisher’s least significant differ-
ence tests were used for post-hoc comparisons between geno-
types and time points for callus area, per cent cartilage, and 
per cent mineralized tissue.
Fracture callus eicosanoid levels
To determine how loss of COX-1, COX-2, and 5-LO activ-
ity affects eicosanoid synthesis during fracture healing, callus 
eicosanoid levels were measured 4 days after fracture during 
the inflammatory phase of healing. To inhibit all cyclooxygen-
ase activity, some COX-1KO and COX-2KO mice were treated, 
respectively, with the COX-2 selective inhibitor rofecoxib (30 
mg/kg VIOXX; Merck, West Point, PA), or the COX-1 selec-
tive inhibitor SC-560 (30 mg/kg; Cayman Chemicals, Ann 
Arbor, MI) by oral gavage using 1% methylcellulose as carrier 
2 h before killing on day 4 after fracture (Smith et al. 1998, 
Chan et al. 1999). Each fracture callus was rapidly resected 
and flash frozen in liquid nitrogen. Eicosanoids were isolated 
by extracting the pulverized sample into M-PER buffer (Pierce 
Biotechnology, Inc., Rockford, IL) and then purifying the eico-
sanoid fraction by sequential methanol and C18 solid phase 
extractions  as  described  previously  (Simon  and  O’Connor 
2007). PGE2, PGF2a, and LTB4 levels were measured using 
enzyme-linked immunoassays (Cayman Chemicals) and nor-
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determined using the bicinchoninic acid assay method and an 
aliquot of the M-PER extract (Smith et al. 1985). Values for 
the C57BL/6 and 5-LOKO samples were compared using Stu-
dent’s t-tests because of genetic background differences with 
the cyclooxygenase-deficient strains, which includes loss of 
secreted phospholipase A2 activity in C57BL/6 mice (Kennedy 
et al. 1995). Values for the other strains and the rofecoxib and 
SC-560 treatment groups were tested for significance using 
ANOVA (p < 0.001) before using Fisher’s least significant dif-
ference tests to identify differences between strains and the 
rofecoxib and SC-560 treatment groups. 
Results
Accelerated and enhanced fracture healing in 
5-LOKO mice
Fracture healing was initially assessed in the 5-LOKO mice by 
radiography (Figure 1). We observed a mineralized callus at 
the periphery of the fracture site by 7 days after fracture in the 
5-LOKO mice as compared to 10 days in the C57BL/6 mice. 
After 10 days of healing, a large mineralized callus was appar-
ent in the 5-LOKO mice, which was similar in appearance to 
the 14-day post-fracture callus of the C57BL/6 mice. Fracture 
bridging was apparent by 14 days after fracture in the 5-LOKO 
mice  but  not  until  21  days  after  fracture  in  the  C57BL/6 
mice. Fracture callus size appeared reduced after 21 days of 
healing in the 5-LOKO mice as compared to 28 days in the 
C57BL/6 mice. While the temporal pattern of fracture heal-
ing in the C57BL/6 mice was similar to what was previously 
observed in outbred (ICR) and inbred (C57BL/6, DBA/2, and 
C3H) strains of mice, healing appeared to be accelerated in the 
5-LOKO mice (Manigrasso and O’Connor 2004, Manigrasso 
and O’Connor 2008).
Fractured femurs from C57BL/6 and 5-LOKO mice were 
harvested at 7, 10, 14, and 21 days after fracture for histo-
morphometric analysis (n = 5 for each genotype at each time 
point). Callus morphology appeared relatively normal in the 
5-LOKO  mice,  with  cartilage  juxtaposed  between  the  frac-
ture site and newly formed bone at the periphery of the callus 
(Figure 2). These observations indicate that fractures heal via 
endochondral ossification in 5-LOKO mice. For both mouse 
strains, callus area peaked at 14 days after fracture (p < 0.005 
vs. 21 days) (Figure 3A). The proportion of callus cartilage in 
the 5-LOKO mice was almost 4 times greater than that from 
the C57BL/6 mice at 7 days after fracture (Figure 3B). By 10 
days after fracture, the proportion of callus cartilage declined 
in the 5-LOKO mice, but peaked in the C57BL/6 mice. Further 
reductions in callus per cent cartilage were noted at 14 and 
21 days after fracture for both mouse strains. The proportion 
of callus mineralized tissue was almost 2-fold higher in the 
5-LOKO mice at 7 days after fracture and remained higher at 
10 days after fracture as compared to the C57BL/6 samples 
(Figure 3C). By 14 and 21 days after fracture, no statistically 
significant difference in the percentage of callus mineralized 
tissue was found between the mouse strains. The data indicate 
that bone regeneration occurs through an accelerated endo-
chondral ossification process in the 5-LOKO mice.
Fracture  callus  mechanical  properties  were  measured  in 
the 5-LOKO and C57BL/6 mice after 4 and 12 weeks of heal-
ing (Figure 4). Contralateral femurs from each mouse were 
also mechanically tested to failure in torsion (Table). Despite 
having the same genetic background, femur morphology was 
different between the C57BL/6 and 5-LOKO strains (Table). 
The better structural properties of the unfractured, contralat-
eral C57BL/6 femurs probably relates to the larger diameter of 
these bones as compared to their 5-LOKO counterparts. Because 
of the baseline differences in femoral mechanical properties, 
Figure 1. Radiographic examination of fracture healing in 5-LOKO mice 
and  control  C57BL/6  mice.  Shown  are  serial  dorsal-ventral  radio-
graphs made from a C57BL/6 mouse (column A) and a 5-LOKO mouse 
(column B) of identical age and genetic background at 7, 10, 14, 21, 
and 28 days after fracture, as indicated. 
Figure 2. Fractures heal by endochondral ossification in 5-LOKO mice. 
Shown are fracture callus specimens from control C57BL/6 mice (A), 
and 5-LOKO mice (B) 7 days after fracture. Specimens were embed-
ded in polymethylmethacrylate, sectioned, and stained with Stevenel’s 
blue and van Gieson’s picrofuchsin to identify mineralized tissue (Bn; 
red) and proteoglycan-rich cartilage (Ca; deep blue). The fracture site 
(Fx) is in the lower, left quadrant of each image. Digital images were 
collected at the same magnification and the white bar in panel A cor-
responds to 500 μm. In the 5-LOKO specimen, a portion of the femoral 
cortical bone was lost during preparation (M).Acta Orthopaedica 2010; 81 (6): 748–755  751
fracture callus mechanical properties were normalized to the 
contralateral femur values as a percentage. Normalized peak 
torque and maximum rigidity of the 5-LOKO fracture calluses 
were approximately 20% and 40% higher than the C57BL/6 
values after 4 weeks of healing. Similarly, normalized maxi-
mum shear stress and shear modulus were approximately 40% 
and 70% higher in the 5-LOKO mice after 4 weeks of healing. 
By 12 weeks, normalized peak torque and maximum shear 
stress remained higher in the 5-LOKO mouse fractures than in 
the C57BL/6 mice. The mechanical testing data demonstrate 
that the 5-LOKO fracture callus regains structural and material 
properties sooner than the fracture callus in control C57BL/6 
mice. 
Fracture callus eicosanoid levels in COX-1KO, COX-
2KO, and 5-LOKO mice
The  effects  of  lost  COX-1,  COX-2,  and  5-LO  activity  on 
PGE2, PGF2a, and LTB4 synthesis was measured at day 4 
after fracture (Figure 5). Surprisingly, callus PGE2 levels were 
more than 3-fold higher in the COX-1KO and COX-2KO callus 
samples than in the COX-2HET samples (Figure 5A). Treat-
ment of the COX-1KO mice with rofecoxib to inhibit COX-2 
dramatically reduced callus PGE2 levels and, similarly, treat-
ment of the COX-2KO mice with SC-560 to inhibit COX-1 
dramatically reduced callus PGE2 levels. No statistically sig-
nificant effect on callus PGE2 levels was seen in the 5-LOKO 
mice (p = 0.1 vs. C57BL/6).
Figure  3.  Endochondral  ossification  is  accelerated  in  5-LOKO  mice. 
Callus area (A), percent cartilage (B), and percent mineralized tissue 
(C) were measured for femoral fracture specimens at 7, 10, 14, and 
21 days after fracture. Group size was 5 at each time point for the 
C57BL/6 strain (blue) and 5-LOKO strain (green). Each rectangle repre-
sents the 25th and 75th percentiles and the median value is indicated 
with a line. Differences between the C57BL/6 and 5-LOKO samples are 
indicated with the corresponding p-values above the x-axis.
Contralateral mechanical values for unfractured femurs
  A  B  C  D  E  F  G  H  I  J
                 
C57BL/6  14–16  11  14.67 (0.26)  1.73 (0.07)  1.20 (0.05)  31.9 (5.0)  819 (200)  144 (30)  4.2 (1.0)
5-LOKO  14–16  11  14.30 (0.21)  1.64 (0.08)  1.16 (0.05)  24.8 (4.9)  688 (168)  126 (28)  4.2 (1.0)
  p-value  —  —  0.002  0.011  0.077  0.003  0.111  0.176  0.997
C57BL/6  22–24  11  15.26 (0.21)  1.77 (0.10)  1.23 (0.04)  37.2 (8.4)  784 (208)  156 (37)  3.8 (1.2)
5-LOKO  22–24  8  15.11 (0.39)  1.53 (0.07)  1.17 (0.03)  23.8 (5.7)  645 (157)  130 (29)  4.5 (0.8)
  p-value  —  —  0.293  < 0.001  0.002  0.001  0.131  0.117  0.130
A  Genotype 
B  Age (weeks) 
C Sample size 
D Length (mm) 
E  Max. diameter (mm) 
F  Min. diameter (mm) 
G Peak torque (Nmm) 
H Max. rigidity (Nmm2/rad) 
I  Max. shear stress (MPa) 
J  Shear modulus (Ga)752  Acta Orthopaedica 2010; 81 (6): 748–755
In contrast to PGE2, callus PGF2a levels were significantly 
lower in the COX-2KO mice as compared to the other mouse 
strains, and treatment with SC-560 to inhibit COX-1 caused 
no further reduction in PGF2a levels (p = 0.9). Callus PGF2a 
levels were also reduced in the COX-1KO mice, but they were 
also higher than in the COX-2KO mice (p = 0.04). Treatment 
of COX-1KO mice with rofecoxib to inhibit COX-2 further 
reduced callus PGF2a levels (p = 0.04) to values similar to 
those found in the COX-2KO mice (p = 0.7). No significant 
effect on callus PGF2a level was detected in the 5-LOKO mice 
(p = 0.4 vs. C57BL/6).
As expected, callus LTB4 levels were low in the 5-LOKO 
mice. Conversely, they were almost 2-fold higher in the COX-
1KO callus samples (p = 0.02) than in the B6;129P2 samples, 
while COX-2KO callus LTB4 levels were over 4-fold higher 
than in the B6;129P2 samples (p < 0.001) and over 2-fold 
higher than in the COX-1KO samples (p < 0.001). Treatment 
of COX-1KO mice with rofecoxib had no significant effect on 
callus LTB4 levels, but treatment of the COX-2KO mice with 
SC-560 caused a 3.5-fold decrease in callus LTB4 levels.
Discussion
The normal functions of 5-LO in bone metabolism are not well 
described. Genetic loss of 5-LO activity alters bone morphol-
ogy (Table) and increases cortical bone thickness (Bonewald 
et al. 1997). Leukotrienes produced via 5-LO can stimulate 
osteoclast activity, suggesting that the increased cortical thick-
ness found in 5-LOKO mice may be associated with reduced 
osteoclast activity (Gallwitz et al. 1993, Garcia et al. 1996, 
Flynn et al. 1999). 
Our findings indicate that endochondral ossification during 
fracture healing is accelerated in 5-LOKO mice, leading to 
reduced bridging time and enhanced biomechanical proper-
ties of the callus (Figures 1-4). The fracture calluses of the 
5-LOKO  mice  obtained  greater  maximum  shear  stress  and 
shear modulus sooner than the C57BL/6 controls. Whether 
the enhanced material properties are a direct consequence of 
lost 5-LO activity or an indirect consequence of earlier bridg-
ing remains to be determined. These experimental results sup-
port the hypothesis that 5-LO metabolites such as LTB4 can 
Figure 4. Fracture calluses from 5-LOKO mice have enhanced mechanical properties. Fractured and contralateral 
femurs after 28 days (blue) and 84 days (green) of healing from control C57BL/6 mice (n = 11 at 28 and 84 days) 
and 5-LOKO mice (n = 11 and 8 at 28 and 84 days, respectively) were mechanically tested to failure in torsion. Peak 
torque (panel A), maximum rigidity (panel B), maximum shear stress (panel C), and shear modulus (panel D) were 
calculated from the torque to angular displacement curves and callus dimensions. Fractured femur values were nor-
malized to values from the contralateral femur of that mouse as a percentage. The limits of each rectangle represent 
the 25th and 75th percentile of the normalized values. The median value is indicated in each rectangle. The 5th and 
95th percentile values are shown below and above each rectangle for those with group sizes of 11. Normalized values 
were compared between genotypes at each time point and p-values are indicated in each graph above the x-axis. Acta Orthopaedica 2010; 81 (6): 748–755  753
impede fracture healing. Indeed, in vitro studies have shown 
that LTB4 treatment can impede osteoblast activity (Ren and 
Dziak 1991, Traianedes et al. 1998).
Measurement of eicosanoid levels in fracture callus sup-
ports the initial hypothesis that loss of COX-2 activity can 
lead to shunting of arachidonic acid into the 5-LO pathway, 
since 4-fold more LTB4 was found in the COX-2KO fracture 
callus (67 pg/mg of protein) than in the B6;129P2 controls 
(15 pg/mg of protein) (Figure 5). While the 2-fold increase 
in COX-1KO callus LTB4 (29 pg/mg of protein) also supports 
an arachidonic acid shunting mechanism, the magnitude of 
callus LTB4 levels in the COX-1KO mice may not be sufficient 
to impair fracture healing. Unexpectedly, callus PGE2 levels 
were dramatically higher in the COX-1KO callus (3-fold) and 
COX-2KO callus (4-fold) than in the B6;129P2 controls. Thus, 
impaired fracture healing in COX-2KO mice does not appear 
to be caused by lack of PGE2. This suggests that therapies 
designed to activate the EP2 or EP4 receptors for PGE2 may 
be enhancing healing by a non-specific mechanism (Li et al. 
2003, 2005, Paralkar et al. 2003, Tanaka et al. 2004). 
Perhaps more intriguing was the observation that PGF2a syn-
thesis appears to be dependent upon COX-2 activity. This sug-
gests that COX-2-dependent PGF2a synthesis may be critical 
for endochondral ossification during fracture healing. Indeed, 
glycosaminoglycan synthesis and the expression of type II col-
lagen and aggrecan were stimulated in human articular chon-
drocyte pellet cultures treated with PGF2a, to a lesser extent 
by PGD2, but not by PGE2 (Jakob et al. 2004). PGF2a treat-
ment also stimulated replication and sulfate incorporation by 
rat  RCJ3.1C5.18  chondrocytes  at  levels  10–100  fold  lower 
than PGE2 (Lowe et al. 1996). Analysis of tissue prostaglandin 
levels during demineralized bone matrix-induced heterotopic 
ossification  in  rats  showed  that  chondrocyte  differentiation 
and progression into hypertrophy correlated with peak PGF2a 
levels (Wientroub et al. 1983). Thus, lack of PGF2a correlates 
well with impaired fracture healing in COX-2KO mice. Unlike 
COX-2KO mice, PGF2a levels in COX-1KO mice appear to be 
sufficient since fracture healing proceeds normally in COX-
1KO mice (Simon et al. 2002). Why PGF2a levels were lower 
in the COX-1KO callus as compared to the B6;129P2 controls 
but higher than in COX-2KO callus is not known. The differ-
ences could relate to preferential coupling of PGF2a synthase 
to heterodimers of COX-1 and COX-2 as compared to COX-2 
homodimers (which would be the only available form of cyclo-
oxygenase in COX-1KO mice), and failure of PGF2a synthase 
to couple with COX-1 homodimers (which would be the only 
available cyclooxygenase form in COX-2KO mice) (Yu et al. 
2006, Yuan et al. 2006). Genetic ablation of COX-1 or COX-2 
may also alter the temporal pattern of prostaglandin synthesis. 
We only measured prostaglandin levels at a single time point 
after  fracture;  additional  experiments  are  needed  to  extend 
these results and confirm when and to what level the synthesis 
of each prostaglandin peaks during fracture healing. It is likely 
that the bioactive lipids synthesized via COX-2 and 5-LO have 
a multiplicity of effects during tissue regeneration or repair.
The cell types that synthesize and respond to prostaglandins 
or leukotrienes during bone healing are not known. Prosta-
glandins can affect osteoblasts, chondrocytes, and osteoclasts 
(Raisz 1999, Zhang et al. 2004, Clark et al. 2005). It has also 
been suggested that prostaglandins can affect fracture callus 
Figure 5. Loss of COX-1, COX-2, or 5-LO function alters callus eico-
sanoid  levels.  Rectangles  represent  the  25th  and  75th  percentiles 
with median values shown for fracture callus PGE2 levels (A), PGF2a 
levels (B), and LTB4 levels (C) measured 4 days after fracture in control 
B6;129P2 mice (n = 6), COX-2HET mice (n = 6), COX-1KO mice (n = 4), 
COX-1KO mice treated with 30 mg/kg of rofecoxib (n = 3), COX-2KO 
mice (n = 6), COX-2KO mice treated with 30 mg/kg of SC-560 (n = 5), 
control C57BL/6 mice (n = 6), and 5-LOKO mice (n = 6). Significant 
differences are indicated as a, p < 0.001 vs. COX-2HET; b, p < 0.001 
vs. COX-1KO; c, p < 0.001 vs. COX-2KO; d, p = 0.04 vs. COX-1KO; e, p 
= 0.02 vs COX-2HET; and f, p = 0.002 vs. C57BL/6. Red bars indicate 
values from mice with the mixed B6;129P2 background and yellow 
bars indicate values from mice with the C57BL/6 background. 754  Acta Orthopaedica 2010; 81 (6): 748–755
mesenchymal cells (Zhang et al. 2002). Much less is known 
about  effects  of  leukotrienes  on  these  cell  types  (Ren  and 
Dziak 1991, Traianedes et al. 1998). Prostaglandins also have 
proangiogenic effects; thus, reduced angiogenesis may under-
lie—at least in part—the impaired fracture healing response 
caused by loss of COX-2 function (Form and Auerbach 1983, 
Seno et al. 2002). The expression of 5-LO and synthesis of 
leukotrienes occurs primarily in cells of the myeloid lineage 
(Steinhilber  1994).  However,  5-LO  expression  in  primary 
cultures of human osteoblasts has been detected (Maxis et 
al. 2006). It is likely that the bioactive lipids synthesized via 
COX-2 and 5-LO have multiple effects during tissue regenera-
tion or repair.
Our study shows that 5-LO negatively regulates fracture 
healing. In contrast, previous studies have shown that COX-2 
is a positive regulator of fracture healing (Simon et al. 2002, 
Simon and O’Connor 2007). Thus, two enzymes that use the 
same lipid substrate to produce different bioactive lipids have 
diametric effects on bone regeneration. Consistent with these 
results, inhibition of 5-LO with an orally delivered drug has 
been  shown  to  accelerate  and  enhance  fracture  healing  in 
another animal model (Cottrell and O’Connor 2009). Phar-
macological or genetic manipulation of the arachidonic acid 
metabolic and signaling pathways to alter COX-2 and 5-LO 
activity  may  be  a  means  to  accelerate  and  enhance  tissue 
repair or regeneration.
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